SCHEMBL6880720

SCHEMBL6880720

CC(C)c1cccc(S(=O)(=O)Nc2ccccc2)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGR P06401 4/20 0.64
POLB P06746 1/20 0.59
KEAP1 Q14145 2/20 0.59
IL1RN P18510 1/20 0.59
ERAP1 Q9NZ08 1/20 0.59
KMT2A Q03164 3/20 0.56
MEN1 O00255 2/20 0.56
PKM P14618 2/20 0.56
ALDH1A1 P00352 1/20 0.56
MAPT P10636 1/20 0.54
MAPK1 P28482 1/20 0.54
HTT P42858 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
HTR6 P50406 2/20 0.52
HDAC2 Q92769 1/20 0.52
HDAC8 Q9BY41 1/20 0.52
HDAC6 Q9UBN7 1/20 0.52
CA12 O43570 2/20 0.51
CA9 Q16790 2/20 0.51
CA1 P00915 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10169497 0.90 HTR6 (0.59) PGRPOLBKEAP1IL1RNERAP1
SCHEMBL27115811 0.86 PGR (0.63) PGRPOLBKMT2AMEN1PKM
SCHEMBL8081768 0.82 KEAP1 (0.79) PGRPOLBKEAP1IL1RNERAP1
SCHEMBL13995037 0.81 PGR (0.69) PGRPOLBKEAP1IL1RNERAP1
SCHEMBL12278151 0.80 TNNI3K (0.62) PGRALDH1A1MAPTHTTSMN1; SMN2
SCHEMBL9267405 0.79 MEN1 (0.62) POLBKMT2AMEN1ALDH1A1GAA
SCHEMBL23988607 0.79 PGR (0.54) PGRPOLBKMT2AMEN1PKM
SCHEMBL15474323 0.78 CA2 (0.61) PGRKMT2AMEN1ALDH1A1MAPT
SCHEMBL15690985 0.78 KEAP1 (0.66) PGRPOLBKEAP1IL1RNERAP1
SCHEMBL12089569 0.78 CA2 (0.51) PGRALDH1A1MAPTHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024044778-A2 NOVEL MODULATORS OF FSHR AND USES THEREOF CELMATIX INC. (US) 2024-02-29 WO disclosed
WO-2024044757-A1 AMINOPYRIMIDINE AND AMINOTRIAZINE DERIVATIVES AS MYC PROTEIN MODULATORS Sanford Burnham Prebys Medical Discovery Institute (US) 2024-02-29 WO disclosed
US-20130040998-A1 FLUORINATED HDAC INHIBITORS AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2013-02-14 US disclosed
WO-2011084991-A2 FLUORINATED HDAC INHIBITORS AND USES THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2011-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130040998-A1 FLUORINATED HDAC INHIBITORS AND USES THEREOF HDAC1, HDAC5, HDAC6 PGR 4523/4885POLB 1226/4885KEAP1 747/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.